These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
257 related articles for article (PubMed ID: 26435014)
1. The perspective of caffeine and caffeine derived compounds in therapy. Pohanka M Bratisl Lek Listy; 2015; 116(9):520-30. PubMed ID: 26435014 [TBL] [Abstract][Full Text] [Related]
2. 1,3-Dialkyl-substituted tetrahydropyrimido[1,2-f]purine-2,4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases. Koch P; Akkari R; Brunschweiger A; Borrmann T; Schlenk M; Küppers P; Köse M; Radjainia H; Hockemeyer J; Drabczyńska A; Kieć-Kononowicz K; Müller CE Bioorg Med Chem; 2013 Dec; 21(23):7435-52. PubMed ID: 24139167 [TBL] [Abstract][Full Text] [Related]
3. Role of Caffeine in the Age-related Neurodegenerative Diseases: A Review. Pohanka M Mini Rev Med Chem; 2022; 22(21):2726-2735. PubMed ID: 35422212 [TBL] [Abstract][Full Text] [Related]
4. Using caffeine and other adenosine receptor antagonists and agonists as therapeutic tools against neurodegenerative diseases: a review. Rivera-Oliver M; Díaz-Ríos M Life Sci; 2014 Apr; 101(1-2):1-9. PubMed ID: 24530739 [TBL] [Abstract][Full Text] [Related]
5. Impacts of methylxanthines and adenosine receptors on neurodegeneration: human and experimental studies. Chen JF; Chern Y Handb Exp Pharmacol; 2011; (200):267-310. PubMed ID: 20859800 [TBL] [Abstract][Full Text] [Related]
7. Xanthine derivatives in the heart: blessed or cursed? Szentmiklósi AJ; Cseppentō A; Gesztelyi R; Zsuga J; Körtvély A; Harmati G; Nánási PP Curr Med Chem; 2011; 18(24):3695-706. PubMed ID: 21774759 [TBL] [Abstract][Full Text] [Related]
8. Molecular and pharmacodynamic interactions between caffeine and dopaminergic system. Voiculescu M; Ghiță I; Segărceanu A; Fulga I; Coman O J Med Life; 2014; 7 Spec No. 4(Spec Iss 4):30-8. PubMed ID: 27057246 [TBL] [Abstract][Full Text] [Related]
9. Effect of caffeine, caffeic acid and their various combinations on enzymes of cholinergic, monoaminergic and purinergic systems critical to neurodegeneration in rat brain-In vitro. Akomolafe SF; Akinyemi AJ; Ogunsuyi OB; Oyeleye SI; Oboh G; Adeoyo OO; Allismith YR Neurotoxicology; 2017 Sep; 62():6-13. PubMed ID: 28465162 [TBL] [Abstract][Full Text] [Related]
10. Ostracising caffeine from the pharmacological arsenal for attention-deficit hyperactivity disorder--was this a correct decision? A literature review. Ioannidis K; Chamberlain SR; Müller U J Psychopharmacol; 2014 Sep; 28(9):830-6. PubMed ID: 24989644 [TBL] [Abstract][Full Text] [Related]
11. Differences between the nonselective adenosine receptor antagonists caffeine and theophylline in motor and mood effects: studies using medium to high doses in animal models. López-Cruz L; Pardo M; Salamone JD; Correa M Behav Brain Res; 2014 Aug; 270():213-22. PubMed ID: 24859174 [TBL] [Abstract][Full Text] [Related]
13. The Medicinal Chemistry of Caffeine. Faudone G; Arifi S; Merk D J Med Chem; 2021 Jun; 64(11):7156-7178. PubMed ID: 34019396 [TBL] [Abstract][Full Text] [Related]
14. [Caffeine, Chocolate and Adenosine A2A Receptor Antagonists in the Treatment of Parkinson's Disease]. Reichmann H Fortschr Neurol Psychiatr; 2023 Jun; 91(6):256-261. PubMed ID: 35584767 [TBL] [Abstract][Full Text] [Related]
15. Astra Award Lecture. Adenosine, adenosine receptors and the actions of caffeine. Fredholm BB Pharmacol Toxicol; 1995 Feb; 76(2):93-101. PubMed ID: 7746802 [TBL] [Abstract][Full Text] [Related]
16. [Coffee and caffeine - enemies or alliantes of a cardiologist?]. Dworzański W; Burdan F; Szumiło M; Jaskólska A; Anielska E Kardiol Pol; 2011; 69(2):173-6. PubMed ID: 21332064 [TBL] [Abstract][Full Text] [Related]
17. Caffeine as a lead compound for the design of therapeutic agents for the treatment of Parkinson's disease. Petzer JP; Petzer A Curr Med Chem; 2015; 22(8):975-88. PubMed ID: 25544641 [TBL] [Abstract][Full Text] [Related]